Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Nov 29 10:35AM ET
Dollar change
Percentage change
Index- P/E76.09 EPS (ttm)0.28 Insider Own2.97% Shs Outstand323.95M Perf Week0.61%
Market Cap6.64B Forward P/E21.40 EPS next Y1.00 Insider Trans-2.23% Shs Float301.75M Perf Month5.48%
Income92.07M PEG4.00 EPS next Q0.21 Inst Own85.61% Short Float / Ratio3.21% / 4.27 Perf Quarter-5.11%
Sales1.77B P/S3.74 EPS this Y11.99% Inst Trans-1.93% Short Interest9.70M Perf Half Y10.74%
Book/sh7.55 P/B2.83 EPS next Y59.07% ROA3.10% Target Price25.82 Perf Year27.16%
Cash/sh3.55 P/C6.02 EPS next 5Y19.00% ROE3.81% 52W Range15.32 - 22.80 Perf YTD33.10%
Dividend- P/FCF18.07 EPS past 5Y2.77% ROI3.63% 52W High-6.34% Beta0.55
Dividend %- Quick Ratio3.76 Sales past 5Y32.32% Gross Margin96.24% 52W Low39.36% ATR0.54
Employees1223 Current Ratio3.83 Sales Q/Q14.62% Oper. Margin2.31% RSI (14)52.55 Volatility1.89% 2.46%
OptionableYes Debt/Eq0.08 EPS Q/Q-98.53% Profit Margin5.19% Rel Volume0.53 Prev Close21.05
ShortableYes LT Debt/Eq0.08 EarningsNov 01 AMC Payout0.00% Avg Volume2.27M Price21.35
Recom1.61 SMA201.40% SMA500.58% SMA2007.31% Volume250,710 Change1.43%
Date Action Analyst Rating Change Price Target Change
Sep-26-23Initiated H.C. Wainwright Buy $28
Aug-22-23Reiterated Oppenheimer Outperform $25 → $29
Aug-08-23Initiated SVB Securities Market Perform $18
Jul-11-23Resumed Morgan Stanley Equal-Weight $21
May-10-23Resumed Piper Sandler Overweight $28
Mar-09-23Initiated Wells Fargo Overweight $23
Jan-26-23Initiated Credit Suisse Outperform $29
Oct-18-22Initiated JMP Securities Mkt Outperform $26
Jun-24-22Initiated BMO Capital Markets Outperform $28
Nov-19-21Initiated Piper Sandler Overweight $34
Today 10:45AM
Nov-21-23 04:05PM
Nov-17-23 01:33PM
Nov-10-23 09:00AM
Nov-09-23 04:43PM
05:24PM Loading…
Nov-08-23 05:24PM
Nov-06-23 09:47AM
Nov-03-23 12:11PM
Nov-02-23 11:23AM
Nov-01-23 07:00PM
Oct-30-23 10:00AM
05:06AM Loading…
Oct-28-23 05:06AM
Oct-27-23 04:58AM
Oct-26-23 10:02AM
Oct-25-23 10:01AM
Oct-22-23 02:30AM
Oct-19-23 06:51PM
Oct-18-23 04:05PM
Oct-12-23 11:40AM
Oct-09-23 02:03AM
Oct-02-23 09:49AM
Sep-20-23 02:15PM
Sep-18-23 09:16AM
05:06AM Loading…
Sep-16-23 05:06AM
Sep-15-23 10:23AM
Sep-13-23 11:23AM
Sep-12-23 08:00AM
Sep-11-23 12:31PM
Sep-08-23 11:30AM
Sep-07-23 08:43AM
Sep-06-23 09:33AM
Sep-05-23 11:40AM
Sep-04-23 10:34AM
Sep-01-23 11:31AM
Aug-31-23 04:05PM
Aug-30-23 08:00AM
Aug-29-23 06:52PM
Aug-28-23 09:30AM
Aug-25-23 11:49AM
Aug-24-23 08:00AM
Aug-23-23 04:30PM
Aug-21-23 04:20PM
Aug-18-23 11:40AM
Aug-15-23 01:43PM
Aug-14-23 03:25PM
Aug-12-23 10:04AM
Aug-11-23 07:15PM
Aug-10-23 09:15AM
Aug-08-23 11:37PM
Aug-06-23 07:00AM
Aug-02-23 12:20PM
Aug-01-23 07:30PM
Jul-31-23 09:58AM
Jul-27-23 07:30AM
Jul-26-23 11:30AM
Jul-25-23 11:40AM
Jul-24-23 03:06PM
Jul-23-23 04:00PM
Jul-20-23 08:08AM
Jul-18-23 04:05PM
Jun-21-23 08:00PM
Jun-08-23 11:30AM
May-31-23 12:30PM
May-30-23 04:05PM
May-29-23 11:58AM
May-24-23 09:53AM
May-20-23 09:30AM
May-13-23 05:06AM
May-12-23 07:55AM
May-10-23 02:52PM
May-09-23 09:34PM
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Aftab DanaCSO/EVP Disc & Trans ResearchAug 30Sale22.474,600103,362399,943Sep 01 08:15 PM
MORRISSEY MICHAELPresident and CEOAug 28Option Exercise15.31360,0005,511,600945,496Aug 30 09:48 PM
Senner Christopher J.EVP and CFOAug 04Option Exercise14.7460,000884,400631,631Aug 07 09:20 PM
Senner Christopher J.EVP and CFOAug 04Sale20.6860,0001,240,800571,631Aug 07 09:20 PM
Senner Christopher J.EVP and CFOAug 03Option Exercise14.7460,000884,400631,631Aug 07 09:20 PM
Senner Christopher J.EVP and CFOAug 03Sale20.5160,0001,230,600571,631Aug 07 09:20 PM
Haley Patrick J.EVP, CommercialAug 03Sale20.6730,553631,531285,467Aug 07 08:24 PM
Hessekiel JeffreyEVP, General Counsel & SecAug 01Option Exercise14.7455,710821,165627,686Aug 03 08:02 PM
Hessekiel JeffreyEVP, General Counsel & SecAug 01Sale19.6355,7101,093,587571,976Aug 03 08:02 PM
Hessekiel JeffreyEVP, General Counsel & SecApr 05Option Exercise14.7413,930205,328621,365Apr 05 08:57 PM
Hessekiel JeffreyEVP, General Counsel & SecApr 05Sale20.0138,930778,989582,435Apr 05 08:57 PM
WYSZOMIERSKI JACK LDirectorMar 10Option Exercise6.3040,000252,000332,767Mar 14 08:22 PM
WYSZOMIERSKI JACK LDirectorMar 10Sale16.6115,300254,133317,467Mar 14 08:22 PM
Hessekiel JeffreyEVP, General Counsel & SecMar 01Option Exercise14.7427,860410,656605,576Mar 03 07:59 PM
Hessekiel JeffreyEVP, General Counsel & SecMar 01Sale17.1377,8601,333,742527,716Mar 03 07:59 PM
Aftab DanaCSO/EVP Disc & Trans ResearchFeb 28Option Exercise14.7482,4901,215,903433,962Mar 01 07:56 PM
Aftab DanaCSO/EVP Disc & Trans ResearchFeb 28Sale17.5082,4901,443,575351,472Mar 01 07:56 PM
Aftab DanaCSO/EVP Disc & Trans ResearchFeb 27Option Exercise14.7410147351,482Mar 01 07:56 PM
Aftab DanaCSO/EVP Disc & Trans ResearchFeb 27Sale17.5010175351,472Mar 01 07:56 PM
Garber Alan MDirectorFeb 21Option Exercise6.3040,000252,00071,417Feb 23 09:08 PM
Garber Alan MDirectorFeb 21Sale17.4940,000699,60031,417Feb 23 09:08 PM
FELDBAUM CARL BDirectorFeb 09Option Exercise6.3040,000252,00058,701Feb 10 07:56 PM
FELDBAUM CARL BDirectorFeb 09Sale17.7840,000711,20018,701Feb 10 07:56 PM
Haley Patrick J.EVP, CommercialFeb 06Option Exercise4.2025,000105,000279,414Feb 08 08:17 PM
Haley Patrick J.EVP, CommercialFeb 06Sale17.3725,000434,250254,414Feb 08 08:17 PM
MORRISSEY MICHAELPresident and CEOJan 24Option Exercise4.20100,000420,000440,655Jan 26 08:59 PM
Lamb PeterEVP, Scientific Strategy & CSODec 15Option Exercise4.2020,00084,000430,958Dec 16 08:09 PM
Lamb PeterEVP, Scientific Strategy & CSODec 15Sale15.8820,000317,600410,958Dec 16 08:09 PM